Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs Sells 7,035 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs sold 7,035 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kymera Therapeutics Trading Down 3.8 %

KYMR stock traded down $1.18 during trading on Monday, hitting $30.17. 982,064 shares of the stock traded hands, compared to its average volume of 578,939. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -12.89 and a beta of 2.18. The company has a 50 day simple moving average of $38.81 and a 200 day simple moving average of $43.66. Kymera Therapeutics, Inc. has a one year low of $29.16 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in KYMR. Blue Trust Inc. increased its position in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. State of Wyoming bought a new stake in shares of Kymera Therapeutics during the fourth quarter valued at approximately $45,000. GF Fund Management CO. LTD. acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV increased its holdings in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. Finally, Quarry LP acquired a new position in Kymera Therapeutics during the 3rd quarter worth $95,000.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. BMO Capital Markets initiated coverage on Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target for the company. Stephens restated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $38.00 to $57.00 in a research report on Monday, December 2nd. UBS Group cut their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.